Literature DB >> 21105782

Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.

Antu K Dey1, Indresh K Srivastava.   

Abstract

Vaccines are the most important preventive measure against infectious diseases. In developing an effective vaccine, besides the primary challenge of identifying the most relevant immunogen and efficient regime of immunization, selection of a potent adjuvant and delivery method is equally critical. The formulation of immunogens with different adjuvants may affect the affinity maturation of antibody responses differently, suggesting that the structure of specific epitopes within the immunogen may be influenced by different adjuvants. Thus, developing adjuvants that can efficiently activate both the innate and adaptive arms of the immune system is a major challenge for vaccine researchers. The use of novel adjuvants in combination with novel immunogen design holds great promise towards the goal of enhancing the potency, breadth and durability of vaccines. This article summarizes the different immunopotentiator (and immunomodulators) as well as the delivery systems that are available for vaccine generation and the types of immune responses that each of them induces. Also discussed are adjuvants that have a combination of both immunomodualtory and delivery properties.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21105782     DOI: 10.1586/erv.10.142

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  21 in total

1.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett
Journal:  Vaccine       Date:  2012-02-22       Impact factor: 3.641

3.  Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.

Authors:  Gary R Matyas; Alexander V Mayorov; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Malliga R Iyer; Fuying Li; Zoltan Beck; Kim D Janda; Carl R Alving
Journal:  Vaccine       Date:  2013-04-23       Impact factor: 3.641

4.  The immune space: a concept and template for rationalizing vaccine development.

Authors:  Amapola Manrique; Elizabeth Adams; Dan H Barouch; Pat Fast; Barney S Graham; Jerome H Kim; James G Kublin; Margaret McCluskey; Giuseppe Pantaleo; Harriet L Robinson; Nina Russell; William Snow; Margaret I Johnston
Journal:  AIDS Res Hum Retroviruses       Date:  2014-06-26       Impact factor: 2.205

5.  Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen.

Authors:  Motoyasu Onishi; Koji Ozasa; Kouji Kobiyama; Keiichi Ohata; Mitsutaka Kitano; Keiichi Taniguchi; Tomoyuki Homma; Masanori Kobayashi; Akihiko Sato; Yuko Katakai; Yasuhiro Yasutomi; Edward Wijaya; Yoshinobu Igarashi; Noriyuki Nakatsu; Wataru Ise; Takeshi Inoue; Hiroshi Yamada; Alexis Vandenbon; Daron M Standley; Tomohiro Kurosaki; Cevayir Coban; Taiki Aoshi; Etsushi Kuroda; Ken J Ishii
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

6.  Vaccines and global health.

Authors:  Brian Greenwood; David Salisbury; Adrian V S Hill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

7.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

8.  Immunogenicity of multi-epitope-based vaccine candidates administered with the adjuvant Gp96 against rabies.

Authors:  Yange Niu; Ye Liu; Limin Yang; Hongren Qu; Jingyi Zhao; Rongliang Hu; Jing Li; Wenjun Liu
Journal:  Virol Sin       Date:  2016-04-06       Impact factor: 4.327

9.  Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.

Authors:  Rachel P J Lai; Michael S Seaman; Paul Tonks; Frank Wegmann; David J Seilly; Simon D W Frost; Celia C LaBranche; David C Montefiori; Antu K Dey; Indresh K Srivastava; Quentin Sattentau; Susan W Barnett; Jonathan L Heeney
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

10.  Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine.

Authors:  Erin M Jackson; Melissa M Herbst-Kralovetz
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.